Search Login Register

Type 2 von Willebrand Disease Summary

Description: A subtype of von Willebrand disease that results from qualitative deficiencies of VON WILLEBRAND FACTOR. The subtype is divided into several variants with each variant having a distinctive pattern of PLATELET-interaction.

Also Known As: von Willebrand Disease, Type 2; Type 2A von Willebrand Disease; Type 2B von Willebrand Disease; Type 2M von Willebrand Disease; Type 2N von Willebrand Disease Show All >>

Networked: 197 relevant articles (2 outcomes, 11 trials/studies) for this Disease

Key Drugs and Agents for Type 2 von Willebrand Disease

Efficacy Chart >>
Drugs and Important Biological Agents (IBA) related to treatments:
  1. von Willebrand Factor : 2 outcomes 8 studies in 144 results : IBA
  2. Deamino Arginine Vasopressin (Desmopressin) : 3 studies in 18 results : FDA 16 Generic
  3. Platelet Glycoprotein GPIb-IX Complex (Glycoprotein Ib) : 1 study in 18 results : IBA
  4. Antigens : 1 study in 10 results : IBA
  5. Heparin (Liquaemin) : 1 study in 2 results : FDA 74 Generic
  6. ARC 1779 : 1 study in 2 results : IBA
  7. von Willebrand factor drug combination factor VIII : 1 study in 2 results : IBA
  8. Ristocetin : 19 results : IBA
  9. Factor VIII (Coagulation Factor VIII) : 19 results : IBA
  10. Collagen : 9 results : IBA
Show All >>

Diseases Related to Type 2 von Willebrand Disease

  1. Thrombocytopenia (Thrombopenia)
  2. Hemorrhage
  3. von Willebrand Diseases (von Willebrand's Disease)
  4. Blood Platelet Disorders (Thrombocytopathy)
  5. Hemophilia A (Haemophilia)
Show All >>

Key Therapies for Type 2 von Willebrand Disease

Efficacy Chart >>
  1. Analgesia : 2 results
  2. Esophagectomy : 1 result
  3. Cesarean Section (Caesarean Section) : 1 result
  4. General Anesthesia : 1 result
  5. Intranasal Administration : 1 result

CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.